Sativa Investments Plc (NEX:SATI) CEO Geremy Thomas talks to DirectorsTalk about the Appointment of Sir Breckenridge to the advisory board, share price movement, resolutions at GM, what George Botanicals brings to the portfolio and now with the UK interest in medicinal cannabis is building how the Sativa Foundation play a role in Sativa’s own growth.
Sativa Investments will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.
The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa intends to acquire can either be public or private.
The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.